Allergic rhinitis (AR) is a common chronic disease, combined with a number of comorbid conditions, which reduces the patients’ quality of life of and exert a significant burden on the healthcare system.

OBJECTIVE

To study the effectiveness of the fixed combination of olopatadine hydrochloride/mometasone furoate (OLO/MF) in real-life clinical practice settings in the Russian Federation, as well as to assess the satisfaction with therapy and treatment compliance of patients.

PATIENTS AND METHODS

A number of adult patients equal 1000 aged 18—65 years and 515 children aged 6—17 years, who were prescribed OLO/MF therapy for at least 14 days due to AR, were examined. All patients underwent medical examination before and after treatment. The severity of AR symptoms was assessed by a visual analogue scale (VAS), quality of life indicators — using the SNOT-22 questionnaire.

RESULTS

There has been a statistically significant decrease in the number of complaints, a reduction in the symptoms’ severity and an improvement in the patients’ quality of life on the OLO/MF therapy. The mean score for the SNOT-22 questionnaire has decreased from 52 to 12 scores for adult patients and from 53 to 13 scores for children, the mean score for the VAS has declined from 60 to 14 mm for both populations (p<0.001). Most patients felt relieved from AR symptoms as early as on the first day of treatment. More than 95% of patients/parents of patients and doctors were satisfied or fully satisfied with the therapy effectiveness, more than 98% — with the tolerability. More than 80% of patients did not interrupt the therapy or admitted less than 1 violation per week.

CONCLUSION

Treatment with OLO/MF nasal spray quickly and effectively relieved AR symptoms in adults and children in real-life clinical practice settings. Both patients/legally authorized patients’ representatives and treating physicians were satisfied with the results.